Full history for every metric is available with a Kvantra account
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €bn | 41.4 | 44.1 | 50.7 | 47.6 | 46.6 | 45.6 | 45.4 | 45.8 |
| Operating profit | €bn | 6.95 | 6.20 | ||||||
| Net profit | €bn | -10.5 | 1.0 | 4.2 | -2.9 | -2.6 | -3.6 | -1.7 | 4.5 |
| EPS reported | € | -3.68 | -1.76 | ||||||
| Operating cashflow per share | € | 4.65 | 4.23 | ||||||
| Capex per share | € | 2.53 | 2.75 | ||||||
| FCF per share | € | 2.12 | 1.48 | ||||||
| Free cash flow | €bn | 2.08 | 1.45 | ||||||
| Net debt | €bn | 28.6 | 32.0 | ||||||
| Book value equity | €bn | 25.9 | 29.6 | ||||||
| Book value per share | € | 26.41 | 30.11 | ||||||
| Number of shares | m | 982.42 | 982.42 | ||||||
| DPS (TTM paid) | € | 0.11 | 0.11 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.40 | 1.46 | ||||||
| P/S LTM | x | 0.80 | 0.95 | ||||||
| P/FCF LTM | x | 17.45 | 29.76 | ||||||
| EV/EBITDA LTM | x | 25.35 | 14.80 | ||||||
| EV/Sales LTM | x | 1.47 | 1.66 | ||||||
| Earnings Yield LTM | % | -9.96% | -4.03% | ||||||
| FCF Yield | % | 5.73% | 3.36% | ||||||
| Quality | |||||||||
| ROE | % | -13.95% | -6.10% | ||||||
| ROIC | % | 8.31% | 7.54% | ||||||
| Operating margin | % | 15.26% | 13.67% | ||||||
| Gross margin | % | 59.21% | 59.05% | ||||||
| FCF/Sales | % | 4.57% | 3.20% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -2.21% | -1.73% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | -54.60% | -68.44% | ||||||
| Operating Profit Growth | % | +55.26% | +24.14% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.35% | 0.25% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | -3.51% | -7.58% | ||||||
| FCF/Debt | x | 0.06 | 0.04 | ||||||
| Net Debt/EBITDA | x | 11.62 | 6.72 | ||||||
| EBIT/Net interest | x | 4.04 | 2.43 | ||||||
| Net debt/market cap | % | 78.55% | 74.13% | ||||||
| Net debt/Equity | x | 1.10 | 1.08 | ||||||
| Gross debt/equity | x | 1.44 | 1.30 | ||||||
ETFs that hold Bayer
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| iShares Edge MSCI Europe Value Factor UCITS ETF | IEVL.L | 4 | 3.06% |
| VanEck Agribusiness ETF | MOO | 2 | 7.40% |
| iShares MSCI Europe Health Care Sector UCITS ETF | ESIH.DE | 9 | 2.71% |
| iShares STOXX Europe 600 Health Care UCITS ETF (DE) | EXV4.DE | 10 | 2.58% |
| State Street SPDR MSCI Europe Health Care UCITS ETF | HLTH.L | 9 | 2.69% |
| Xtrackers MSCI Europe Value UCITS ETF 1C | D5BL.DE | 4 | 3.05% |
| Amundi STOXX Europe 600 Industrials UCITS ETF Acc | IND.PA | 3 | 7.41% |
| Xtrackers MSCI Europe Health Care Screened UCITS ETF 1C | DXSE.DE | 9 | 2.80% |
| Desjardins RI Global Multifactor - Fossil Fuel Reserves Free ETF | DRFG.TO | 10 | 1.33% |
| VanEck Natural Resources ETF | HAP | 6 | 3.28% |
Funds with Bayer among their ten largest holdings, largest fund first.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Bayer Aktiengesellschaft (BAYN.DE)
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| iShares Edge MSCI Europe Value Factor UCITS ETF | IEVL.L | 4 | 3.06% |
| VanEck Agribusiness ETF | MOO | 2 | 7.40% |
| iShares MSCI Europe Health Care Sector UCITS ETF | ESIH.DE | 9 | 2.71% |
| iShares STOXX Europe 600 Health Care UCITS ETF (DE) | EXV4.DE | 10 | 2.58% |
| State Street SPDR MSCI Europe Health Care UCITS ETF | HLTH.L | 9 | 2.69% |
| Xtrackers MSCI Europe Value UCITS ETF 1C | D5BL.DE | 4 | 3.05% |
| Amundi STOXX Europe 600 Industrials UCITS ETF Acc | IND.PA | 3 | 7.41% |
| Xtrackers MSCI Europe Health Care Screened UCITS ETF 1C | DXSE.DE | 9 | 2.80% |
| Desjardins RI Global Multifactor - Fossil Fuel Reserves Free ETF | DRFG.TO | 10 | 1.33% |
| VanEck Natural Resources ETF | HAP | 6 | 3.28% |
Funds with Bayer among their ten largest holdings, largest fund first.
Based on consensus from external analysts. Not Kvantra's opinion.
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free